Sanofi Expands its 2016 Agreement with Innate Pharma for Natural Killer Cell Therapies in Oncology
Shots:
- Innate will receive $26.51M up front, ~ $1.43B in preclinical, clinical, regulatory & commercial milestones along with royalties
- Sanofi to get an exclusive license to Innate’s B7H3 ANKET program along with options for 2 additional targets & will be responsible for all development, manufacturing & commercialization upon candidate selection
- In the 2016 agreement, the companies collaborated to develop 2 bispecific NK cell engagers (evaluated by Sanofi’s R&D team) using Innate's technology & Sanofi’s bispecific Ab format along with tumor targets. SAR443579 is being studied in a P-I/II trial for r/r AML, B-ALL, or HR-MDS while another bispecific NK cell engager, SAR445514 entered into IND-enabling studies in 2022
Ref: Sanofi | Image: Sanofi
Related news :- BeiGene Signs an Exclusive Worldwide Collaboration with Shoreline to Develop and Commercialize Genetically Modified NK Cell Therapies
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
